Contact Us
Drug Search Results
More Filters [+]

Flortaucipir (18f)

Alternative Names: flortaucipir (18f), 18f-av-1451, flortaucipir f18, tauvid, Flortaucipir, T-807, T807, T 807
Latest Update: 2025-01-09
Latest Update Note: Clinical Trial Update

Product Description

Avid Radiopharmaceuticals is developing Flortaucipir (18f) as a treatment for Alzheimer's Disease. (Sourced from: https://investor.lilly.com/news-releases/news-release-details/lilly-receives-us-fda-approval-tauvidtm-flortaucipir-f-18)

Mechanisms of Action: Imaging Agent

Novel Mechanism: No

Modality: Diagnostic Agent

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: United States

Approved Indications: Chronic Traumatic Encephalopathy | Alzheimer Disease

Known Adverse Events: Chronic Traumatic Encephalopathy | Alzheimer Disease | Chronic Pain | Headache | Pain Unspecified | Pregnancy Outcomes

Company: Avid Radiopharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Flortaucipir (18f)

Countries in Clinic: United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Alzheimer Disease|Brain Diseases|Lewy Body Disease|Parkinson's Disease|Spinal Diseases|Spinal Injuries

Phase 2: Frontotemporal Dementia|Lewy Body Dementia|Other

Phase 1: Brain Concussion|Cognition Disorders

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT03143374

P3

Recruiting

Brain Diseases|Spinal Diseases|Parkinson's Disease|Spinal Injuries|Alzheimer Disease|Lewy Body Disease

2030-09-01

NCT04263337

P1

Enrolling by invitation

Brain Concussion

2025-12-01

LEARN-Tau

P1

Completed

Cognition Disorders

2023-09-29

2019-002694-63

P2

Active, not recruiting

Other

2022-04-09

Recent News Events

Date

Type

Title

12/09/2024

News Article

 Global Alzheimer's Platform Foundation Announces Strategic Collaboration with Eli Lilly and Company for the Transformative Bio-Hermes-002 Study

05/30/2024

News Article

 AKTIS ONCOLOGY NAMES TYLER BENEDUM, Ph.D., CHIEF TECHNICAL OFFICER

03/08/2024

News Article

 Alzheimer's Drug Discovery Foundation (ADDF) Statement on FDA Decision to Convene Advisory Committee for Donanemab

07/17/2023

News Article

 ADDF Statement on New Results from Donanemab's TRAILBLAZER-ALZ 2 Trial

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions